+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07811869

Evaluating Remibrutinib for Adults With Severe Chronic Pruritus of Unknown Origin in a 52-Week Randomized, Double-Blind, Placebo-Controlled Phase 3 Study

Led by Novartis Pharmaceuticals · Updated on 2026-10-28

180

Participants Needed

10

Research Sites

44 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy, safety, and tolerability of remibrutinib in adults with severe chronic pruritus of unknown origin CPUO, a condition characterized by severe itching without a known cause. This global, phase 3, randomized, double-blind, placebo-controlled trial aims to establish how remibrutinib performs compared to placebo in treating this condition. Participants will go through four study periods over up to 60 weeks. After a screening period of up to 4 weeks, they will enter a 24-week double-blind treatment phase receiving either remibrutinib or placebo. Following this, all participants receive open-label remibrutinib for 28 weeks, including those initially on placebo who switch at Week 24. The study concludes with a 4-week treatment-free safety follow-up. During the study, participants will be regularly assessed for itch severity using the Worst Itch Numerical Rating Scale and Patient Global Impression of Severity sleep disturbance related to itching will also be measured. Safety will be monitored by tracking adverse events throughout the 52-week treatment period. Participants adherence and response to treatment will be closely followed, with all evaluations scheduled at specific time points including baseline, Week 4, Week 12, and Week 24.

CONDITIONS

Brief Title

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here